Drug Profile


Alternative Names: Jaceosidin/eupatilin; Stillen

Latest Information Update: 07 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Cytoprotectives; Phytotherapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Gastric ulcer; Gastritis
  • No development reported Gastro-oesophageal reflux

Most Recent Events

  • 07 Oct 2015 No recent reports of development identified - Preclinical for Gastro-oesophageal reflux in South Korea (PO)
  • 31 Oct 2007 Data presented at the 15th United European Gastroenterology Week (UEGW-2007) added to the adverse events and Peptic Ulcer Disease therapeutic trials sections
  • 01 Aug 2003 Data presented at the Digestive Disease Week - 2003 (DDW-2003) have been added to the Peptic ulcer disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top